Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • Rights Issue 2022
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
      • Management stories
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Rights Issue 2022
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

Press Releases
  • Regulatory Releases
  • All releases
2015
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Non Regulatory
December 7, 2015

Oasmia Pharmaceutical’s Next Generation Anti-cancer Drug Docecal Approved for Clinical Trials

Non Regulatory
December 3, 2015

Interim report for the period May – October 2015

Non Regulatory
November 20, 2015

Oasmia Pharmaceutical’s Lead Human Cancer Drug Paclical® Generates Strong Interest at the 19th Annual Russian Cancer Congress

Non Regulatory
November 5, 2015

Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®

Non Regulatory
November 5, 2015

Oasmia Pharmaceutical AB Announces an Additional and Partial Exercise of Over-Allotment

Non Regulatory
October 30, 2015

Oasmia Pharmaceutical receives order of $7.5 million in end-user value for the Russian market

Non Regulatory
October 29, 2015

Oasmia Pharmaceutical AB Announces Closing of U.S. Initial Public Offering of American Depositary Shares and Warrants and NASDAQ Listing

Non Regulatory
October 28, 2015

Oasmia Pharmaceutical AB Executes First Commercial Order of Paclical for the Russian market

Non Regulatory
October 23, 2015

Oasmia Pharmaceutical AB Announces Pricing of Public Offering of American Depositary Shares and NASDAQ Listing

Non Regulatory
October 20, 2015

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering

Non Regulatory
October 5, 2015

Oasmia Pharmaceutical AB Announces Commercial Launch of Paclical in Russia and CIS Countries

Non Regulatory
September 30, 2015

Communiqué from Oasmia’s Annual General Meeting 2015

Non Regulatory
September 28, 2015

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Adds Warrants

Non Regulatory
September 3, 2015

Interim report for the period May – July 2015

Non Regulatory
August 21, 2015

The Oasmia Pharmaceutiacal Annual Report is now published

Non Regulatory
August 17, 2015

Oasmia Pharmaceutical AB Files Registration Statement on Form F-1/A for its Proposed Public Offering; Announces Investor Roadshow

Non Regulatory
August 4, 2015

Oasmia Pharmaceutical Announces Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®

Non Regulatory
August 3, 2015

Oasmia Pharmaceutical Extends Form F-1/A Registration Statement to Include New Key Material Data and Final Full-Year Financials

Non Regulatory
July 7, 2015

Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing

Non Regulatory
July 7, 2015

Oasmia Pharmaceutical Launches US Brand and Sales Platform

Non Regulatory
July 4, 2015

Year-end report for the fiscal year May 2014 – April 2015

Non Regulatory
May 29, 2015

Changes in Oasmia’s Board of Directors and Management

Non Regulatory
May 7, 2015

Oasmia gives notice of Extraordinary General Meeting

Non Regulatory
April 24, 2015

Results from Oasmia’s Phase III study will be presented at ASCO

Non Regulatory
March 5, 2015

Interim report for the period May 2014 – January 2015

Non Regulatory
February 17, 2015

Oasmia initiates clinical Phase II study with Doxophos Vet for the treatment of canine lymphoma

Investor contact

Cord Communications
IR@vivesto.com
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com